Monosit/ Yüksek Dansiteli Lipoprotein Kolesterol Oranı Stabil Anjina Pektorisi Olan Hastalarda Safen Ven Greft Açıklığını Öngördürebilir mi?

Abstract

Giriş: Dolaşımdaki monosit sayısı yeni aterosklerotik plak gelişimi için öngördürücü bir faktördür. Ayrıca, yüksek dansiteli lipoprotein kolesterol (HDL) ile ateroskleroz arasında güçlü bir ters ilişki vardır. Monosit sayısı/HDL oranının (MHR) yeni bir inflamatuvar belirteç olduğu gösterilmiştir. Biz MHR ile safen ven greft hastalığı (SVGD) arasındaki ilişkiyi araştırmayı amaçladık.

Hastalar ve Yöntem: Toplam 369 hasta 3 gruba bölündü (SVGD olan grup= 150, SVGD olmayan grup= 89, normal koroner arter grubu= 130). Bazal karakteristikler ve laboratuvar parametreleri kayıt edildi ve gruplar arasında karşılaştırıldı.

Bulgular: Bazal karakteristiklere göre SVGD olan ve olmayan gruplarda, SVG yaşı ve sol ventrikül ejeksiyon fraksiyonu haricinde istatistiksel farklılık yoktu. C-reaktif protein, açlık kan şekeri ve ortalama platelet hacmi SVGD olan grupta SVGD olmayan gruba göre daha yüksekti (sırasıyla p değerleri= 0.008, 0.048 ve 0.042). MHR değeri SVGD olan, SVGD olmayan (p= 0.169) ve normal koroner arter grupları (p= 0.364) arasında istatistiksel farklılık göstermedi. CRP, SVGD için bağımsız öngördürücü faktör olarak bulundu.

Sonuç: MHR ve koroner ateroskleroz arasında ilişki yoktu. MHR, SVGD için bir öngördürücü faktör değildi.

Keywords

• Monosit sayısı,yüksek dansiteli lipoprotein kolesterol,ateroskleroz,safen ven greft hastalığı

Does Monocyte/High-Density Lipoprotein Cholesterol Ratio Predict Saphenous Vein Graft Patency in Patients with Stable Angina Pectoris?

Abstract

Introduction: Circulating monocyte count is a predictive factor of new atherosclerotic plaque development. In addition, there is a strong inverse relationship between high-density lipoprotein (HDL) cholesterol and atherosclerosis. It has been shown that the monocyte/HDL cholesterol ratio (MHR) is a novel inflammatory marker. We aimed to investigate the relationship between MHR and saphenous vein graft disease (SVGD).

Patients and Methods: A total of 3 69 patients were divided into 3 groups (positive SVGD group= 150, negative SVGD group= 89, normal coronary artery group= 130). Baseline characteristics and laboratory parameters were recorded and compared among the groups.

Results: There were no significant differences between the positive and negative SVGD groups, except for age of SVG and left ventricular ejection fraction, according to baseline characteristics. C-reactive protein (CRP) levels, fasting blood glucose levels and mean platelet volume were higher in the positive SVGD group than in the negative SVGD group (p= 0.008, 0.048 and 0.042, respectively). MHR was not significantly different between the positive and negative SVGD groups (p= 0.169) and normal coronary artery group (p= 0.364). CRP was found to be an independent predictor factor of SVGD.

Conclusion: There was no association between MHR and coronary atherosclerosis. MHR was not a predictive factor of SVGD.

Keywords

• Monocyte count,high-density lipoprotein cholesterol,atherosclerosis,saphenous vein graft disease

References

1. 1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-619.
2. 2. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005;294:2446-54.
3. 3. Sabik JF, Blackstone EH, Houghtaling PL, Walts PA, Lytle BW. Is reoperation still a risk factor in coronary artery bypass surgery? Ann Thorac Surg 2005;80:1719-27.
4. 4. Parang P, Arora R. Coronary vein graft disease: pathogenesis and prevention. Can J Cardiol 2009;25:57-62.
5. 5. Akyel A, Celik IE, Oksüz F, Cay S, Karadeniz M, Kurtul A, et al. Red blood cell distribution width in saphenous vein graft disease. Can J Cardiol 2013;29:448-51.
6. 6. Yayla Ç, Canpolat U, Akyel A, Yayla KG, Yilmaz S, Açikgöz SK, et al. Association between platelet to lymphocyte ratio and saphenous vein graft disease. Angiology 2016;67:133-8.
7. 7. Tasoglu I, Turak O, Nazli Y, Ozcan F, Colak N, Sahin S, et al. Preoperative neutrophil-lymphocyte ratio and saphenous vein graft patency after coronary artery bypass grafting. Clin Appl Thromb Hemost 2014;20:819-24.
8. 8. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010;7:77-86.

9. 9. Johnsen SH, Fosse E, Joakimsen O, Mathiesen EB, Stensland-Bugge E, Njølstad I, et al. Monocyte count is a predictor of novel plaque formation: a 7-year follow-up study of 2610 persons without carotid plaque at baseline the Tromsø Study. Stroke 2005;36:715-9.
10. 10. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15:1987-94.
11. 11. Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 2014;46:1619-25.
12. 12. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, et al; VA Cooperative Study Group #207/297/364. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 2004;44:2149-56.
13. 13. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5.065 grafts related to survival and reoperation in 1.388 patients during 25 years. J Am Coll Cardiol 1996;28:616-26.
14. 14. Lawrie GM, Lie JT, Morris GC Jr, Beazley HL. Vein graft patency and intimal proliferation after aortocoronary bypass: early and long-term angiopathologic correlations. Am J Cardiol 1976;38:856-62.
15. 15. McGeachie JK, Meagher S, Prendergast FJ. Vein-to-artery grafts: the longterm development of neo-intimal hyperplasia and its relationship to vasa vasorum and sympathetic innervation. Aust N Z J Surg 1989;59:59-65.
16. 16. Kim FY, Marhefka G, Ruggiero NJ, Adams S, Whellan DJ. Saphenous vein graft disease: review of pathophysiology, prevention, and treatment. Cardiol Rev 2013;21:101-9.
17. 17. Iwama Y, Mokuno H, Watanabe Y, Shimada K, Yokoi H, Daida H, et al. Relationship between plasma homocysteine levels and saphenous vein graft disease after coronary artery bypass grafts. Jpn Heart J 2001;42:553-62.
18. 18. Momin A, Melikian N, Wheatcroft SB, Grieve D, John LC, El Gamel A, et al. The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007;134:335-41.
19. 19. Greaves DR, Gordon S. The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J Lipid Res 2009;50(Suppl):S282-6.
20. 20. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009;27:165-97.
21. 21. Diamond MS, Staunton DE, de Fougerolles AR, Stacker SA, Garcia-Aguilar J, Hibbs ML, et al. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol 1990;111:3129-39.
22. 22. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
23. 23. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
24. 24. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-81.
25. 25. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-91.
26. 26. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15:1987-94.
27. 27. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
28. 28. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
29. 29. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008;28:2071-7.
30. 30. Canpolat U, Çetin EH, Cetin S, Aydin S, Akboga MK, Yayla C, et al. Association of monocyte to HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clin Appl Thromb Hemost 2016;22:476-82.
31. 31. Cetin EH, Cetin MS, Canpolat U, Aydin S, Topaloglu S, Aras D, et al. Monocyte/HDL cholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Biomark Med 2015;9:967-77.